Published On: Wed, Oct 19th, 2016

Medivation, Inc. (NASDAQ:MDVN) – Broker Update

Below are the most recently updated broker updates which include ratings and price targets for Medivation, Inc. (NASDAQ:MDVN).

09/13/2016 – Broker: SunTrust Rating: neutral reiteration

08/23/2016 – Broker: Stifel Nicolaus Rating: hold downgrade

08/23/2016 – Broker: BMO Capital Markets Rating: market perform New Target: 81.5 reiteration

08/23/2016 – Broker: Credit Suisse Rating: neutral New Target: 81.5 downgrade

08/23/2016 – Broker: Maxim Group Rating: hold New Target: 81.5 downgrade

08/22/2016 – Broker: Canaccord Genuity Rating: buy New Target: 82 reiteration

08/22/2016 – Broker: Citigroup Rating: neutral downgrade

08/22/2016 – Broker: Brean Capital Rating: hold downgrade

08/22/2016 – Broker: Wedbush Rating: neutral downgrade

08/22/2016 – Broker: Barclays Rating: equal-weight downgrade

08/10/2016 – Broker: JMP Securities Rating: market perform downgrade

08/10/2016 – Broker: Jefferies Rating: hold New Target: 60 reiteration

07/07/2016 – Broker: RBC Capital Rating: sector perform New Target: 70 reiteration

07/07/2016 – Broker: Leerink Swann Rating: market perform New Target: 64 reiteration

04/28/2016 – Broker: Goldman Sachs Rating: neutral New Target: 44 reiteration

The average price target from the most recent broker reports is 70.56

The stock increased +0.00% (+0.00) during the last days session, reaching 81.44 and roughly 0 shares were bought or sold by traders. Medivation, Inc. (NASDAQ:MDVN) has increased by +84.09% over 12 months.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.